ORIC Pharmaceuticals

Contributing Author

Recent Articles by ORIC Pharmaceuticals

Nov-13	ORIC Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates ORIC GlobeNewswire
Nov-13	ORIC Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety ORIC GlobeNewswire
Nov-07	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Nov-06	ORIC Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor ORIC GlobeNewswire
Nov-04	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences ORIC GlobeNewswire
Oct-27	ORIC Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors ORIC GlobeNewswire
Sep-05	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Aug-27	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences ORIC GlobeNewswire
Aug-18	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer ORIC GlobeNewswire
Aug-12	ORIC Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates ORIC GlobeNewswire
Aug-01	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Jul-03	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Jun-06	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
May-28	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing ORIC GlobeNewswire
May-28	ORIC Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC ORIC GlobeNewswire
May-27	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences ORIC GlobeNewswire
May-27	ORIC Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC ORIC GlobeNewswire
May-05	ORIC Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates ORIC GlobeNewswire
May-02	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.